Search
Latest Stories
Don't Miss Out
Get the latest updates and insights delivered to your inbox.

HealthyWomen Editors
The editorial team and staff of HealthyWomen.
Kim Ledgerwood
Editorial Director, HealthyWomen
As HealthyWomen’s editorial director, Kim oversees the production of all content and ensures that it is aligned with our mission, meets our high editorial standards and captures our brand voice.
Kim is an award-winning editor and copywriter with more than 25 years of experience. She started her career as a copywriter and broadcast producer at the Southeast’s largest full-service advertising agency, The Tombras Group. Since then, she has edited and written for a wide variety of clients, ranging from Fortune 500 companies to indie authors across multiple industries and topics.
She holds a bachelor’s degree in communications from the University of North Carolina, Chapel Hill, as well as a master’s degree in communications/advertising from The University of Tennessee, Knoxville.
Kim lives in Maryland with her husband, three children and a menagerie of pets.
Jacquelyne Froeber
Senior Editor, HealthyWomen
Jacquelyne Froeber is an award-winning journalist and editor. She holds a BA in journalism from Michigan State University. She is the former editor-in-chief of Celebrated Living magazine and has editing and writing experience for print and online publications, including Health magazine, Coastal Living magazine and AARP.org.
As a breast cancer survivor, Jacquelyne encourages everyone to perform self-exams and get their yearly mammograms.
Full BioLearn about our editorial policies
New ‘This is ALZ’ Campaign Puts a Face to the Earlier Stages of Alzheimer’s and Expands Understanding of the Disease
Campaign elevates real stories to spotlight empowerment in knowing early
WASHINGTON, D.C. — A new awareness campaign, This is ALZ, launched today to challenge long-held perceptions of Alzheimer’s by revealing what the disease looks like in its earlier stages, when symptoms are mild or have yet to show.
Powered by HealthyWomen, the campaign spotlights the lived experiences of people navigating the earlier stages of Alzheimer’s, from those who are cognitively unimpaired and experience no symptoms, to those who are beginning to experience cognitive impairment with more noticeable symptoms.
Alzheimer’s disease affects more than 7 million Americans, nearly two-thirds of whom are women, with older Black and Hispanic Americans facing a higher risk. Despite its prevalence, awareness of the disease’s earlier stages remains limited. Nearly all Americans (99%) say early-stage diagnosis is important, yet fewer than one in five (16%) say they know a lot about Alzheimer’s, highlighting a critical gap that This is ALZ aims to address.
“Alzheimer’s is commonly viewed as a disease that only impacts people in its most advanced stages, but the reality is far more nuanced,” said Beth Battaglino, RN-C, CEO of HealthyWomen. “By sharing real stories from people living with the earlier stages, This is ALZ aims to shift perceptions, encourage earlier conversations and help people better understand what’s possible after diagnosis.”
While Alzheimer’s is often associated with its later stages, it develops over time and can present differently in its earlier stages, when changes may be subtle. This is ALZ highlights a broader view of the disease, including how people living with the earlier stages may continue to maintain independence, connection and a sense of purpose after diagnosis.
“People have that thought that your life ends when you get the diagnosis. But I felt like my life was just beginning,” said LauraLee Denler, who is living with the earlier stages of Alzheimer’s and is helping challenge common assumptions about life after diagnosis.
Redefining What’s Possible
At the heart of the campaign are personal stories that challenge stigma and outdated assumptions about Alzheimer’s, demonstrating that people can continue to lead meaningful, engaged lives in the earlier stages of the disease.
“My story is very different. People don't really get that I have Alzheimer's. They see me as kind of young,” said Pako Rios, who is living with the earlier stages of Alzheimer’s and whose experience reflects how the disease can largely remain outwardly invisible in its earlier stages.
Highlighting a New Era of Understanding
Advances in research, diagnosis and treatment are transforming how Alzheimer’s is understood and managed. New diagnostic tools, including U.S. Food and Drug Administration (FDA)-cleared blood-tests, are making it possible to identify the disease earlier than ever before.
Knowing Early Can Help People Live Intentionally
A key message of This is ALZ is that those who know early are taking action and changing what’s possible with their lives. Early awareness can provide individuals and families with time to plan, make informed decisions and focus on what matters most, from health and wellness to care and financial planning. It can also open the door to meaningful conversations and stronger support systems.
“By being diagnosed early, I have a lot more opportunities. It gave me the chance to make decisions about how I want to live my life,” said Kerry Dennis, who is living with the earlier stages of Alzheimer’s and emphasizes how early awareness can support more intentional decision-making.
“Alzheimer’s is too often recognized only in its later stages, leaving many individuals and families without the information they need early on,” said Karyne Jones, President and CEO of NCBA. “Campaigns like This is ALZ are critical to broadening awareness, especially in communities like ours where greater understanding of the earlier stages of Alzheimer’s is needed. By elevating real stories and emphasizing the importance of knowing early, we can help reduce stigma, encourage timely conversations and ensure individuals and families are better equipped to plan, seek care and continue living with purpose.”
Turning Awareness Into Action
By elevating real stories, This is ALZ encourages the public, policymakers and healthcare decision makers to reconsider assumptions about Alzheimer’s and recognize the value of early diagnosis.
This is ALZ is supported by a multi-channel effort to drive awareness and engagement, including the launch of a new website and social channels, advertising, partner outreach, signature story videos, blog content and other educational resources to help increase understanding of the earlier stages of Alzheimer’s.
To learn more and explore stories from those living with the earlier stages of Alzheimer’s, visit ThisisALZ.com.
###
About This is ALZ
This is ALZ is a campaign that highlights the real experiences of people living with the earlier stages of Alzheimer’s. By sharing personal stories, the campaign shows that the disease is just one part of an individual’s story and underscores how knowing early can empower people to live intentionally now and into the future. This is ALZ is powered by HealthyWomen. Learn more at ThisisAlz.com. Follow This is ALZ on social at @thisisalzvoices.
About HealthyWomen
HealthyWomen is the nation’s leading independent, nonprofit health information source for women. HealthyWomen.org was the first website to comprehensively address women’s health and wellness issues and continues to educate women to make informed health decisions by providing objective, fact-based information. For nearly 40 years, women have turned to HealthyWomen for answers to their most important healthcare questions. To learn more, please visit www.HealthyWomen.org. Follow HealthyWomen on Facebook, Twitter, Instagram and LinkedIn.
HealthyWomen developed this initiative with support from and in collaboration with Eli Lilly (Lilly) and Company.
Each case of breast cancer is different, so treatment shouldn't take a one-size-fits-all approach. The Breast Cancer Index (BCI) is a test that can help you get breast cancer care personalized to your unique tumor biology.
Clinicians use the BCI for early-stage hormone receptor-positive (HR+) breast cancer patients to determine the chances that their breast cancer will return somewhere else in their body within 10 years of diagnosis. The results from the BCI can be used to determine whether staying on treatments that block or lower estrogen (anti-estrogen therapy) is likely to reduce that risk.
Considering about 4 out of 5 cases of breast cancer are HR+, the BCI test is an important tool when deciding on a treatment plan for many women.
Recently, the BCI test options were expanded to help patients get more information to help personalize their treatment decisions earlier in their diagnosis.
Here’s what you need to know — and what’s new — about the BCI test.
What is the Breast Cancer Index test?
The BCI test analyzes the activity in 11 genes found in breast cancer tissue to assess how likely the cancer is to grow and spread as well as to determine if staying on anti-estrogen therapy for longer may help lower that risk.
The test is performed by evaluating the biology of a patient’s original tumor sample and uses tissue that was preserved during the original biopsy or breast surgery, so no additional procedures are needed.
Who should get a Breast Cancer Index test?
The BCI test is only for people who’ve been diagnosed with early-stage hormone receptor-positive breast cancer.
Talk to your clinician about the BCI test if you:
- Have been diagnosed with stage 1, stage 2 or stage 3 hormone receptor-positive breast cancer
- Have no cancer in your lymph nodes (also called lymph node-negative disease) or the cancer is lymph-node positive and in one, two or three lymph nodes
- Are considering taking or are already on anti-estrogen therapy and want to know if treatment will help reduce your risk for recurrence
What do the results of the Breast Cancer Index test tell you?
For most women, hot flashes, fatigue, joint pain and other side effects from anti-estrogen therapy seriously affect quality of life. Anti-estrogen therapies also increase the risk for osteoporosis (bone loss), blood clots and other cancers.
The BCI test helps patients and clinicians make important decisions about anti-estrogen therapy, including how long treatment should last.
The results of the BCI test predict:
- Individualized overall risk (0-10 years post-diagnosis) of the treated cancer returning somewhere else in the body (metastatic recurrence)
- Individualized late risk (5-10 years post-diagnosis) of metastatic recurrence
- Whether extended anti-estrogen therapy (past five years) will help reduce the risk for late recurrence
In the past, the BCI test was done five years after diagnosis to determine risk of late recurrence and whether longer anti-estrogen therapy would help reduce that risk. Now, as part of the new expanded BCI option, the test can be done earlier after diagnosis or early in treatment to provide more information that may help clinicians and patients develop a personalized treatment plan from the start.
For example, people who have low enough risk may want to consider a less aggressive treatment plan. For postmenopausal women, this may mean taking anti-estrogen treatments for a shorter amount of time. And women who are at minimal risk and premenopausal may not have to go through ovarian suppression.
Questions to ask your clinician about the Breast Cancer Index test
If you have hormone receptor-positive breast cancer or have a personal history of it, talk to your clinician about the BCI test.
It’s a good idea to write down your thoughts and concerns before the conversation and take them with you to your appointment.
Here are some questions to consider:
- Am I a candidate for the BCI test?
- How long will it take to get the results from the BCI test?
- How will the results affect my treatment plan?
- What are the downsides (if any) to the BCI test?
- Does insurance cover the test?
Final FYI on BCI
A breast cancer diagnosis is scary and overwhelming. But the BCI test can offer some clarity and help some people avoid potentially unnecessary treatments.
The BCI test is the only genomic test available that can predict risk of late distant recurrence and the benefit of extended endocrine therapy in people diagnosed with early-stage hormone receptor-positive breast cancer.
This educational resource was created with support from Hologic, a HealthyWomen Corporate Advisory Council member.










